MoonLake announces FDA clearance for Phase 2 clinical study of the Nanobody® sonelokimab in active psoriatic arthritis
Expected to enroll approximately 200 patients to assess the efficacy and safety of sonelokimab
Eni (NYSE:E) reported quarterly earnings of €1.06 per share. This is a 171.79 percent increase over earnings of €0.39 per share from the same period last year. The company reported €37.30 billion in sales